| abstract |
A compound having antiestrogenic activity is used in a method for the treatment of BC or other estrogen-responsive tumors in a human patient, wherein the method comprises subjecting the patient to a fasting-mimicking diet for a period of 24- 190 hours while the patient is the patient. Being treated with the compound that has antiestrogenic activity, which can be a selective estrogen receptor modulator (SERM), a selective estrogen receptor downregulator (SERD), or an aromatase inhibitor (AI). (Automatic translation with Google Translate, without legal value) |